{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-248760","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.715785+00:00","generated_at":"2026-05-30T07:35:18.718212+00:00","sec_items":["1.01","2.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lyell Immunopharma completes $30M+stock acquisition of ImmPACT Bio, gains CD19/20 CAR T candidate","bullets":["Upfront: $30M cash (adjusted for ~$12M ImmPACT cash) plus 37.5M Lyell shares; contingent milestone shares up to 12.5M and low-single-digit royalty.","IMPT-314 (dual-targeting CD19/20 CAR T) expected to start pivotal trial in 2025 for third-line CAR-naïve B-cell non-Hodgkin lymphoma.","Sumant Ramachandra, former ImmPACT CEO, appointed to Lyell's Board of Directors.","Lyell expects cash to fund operations into 2027 through clinical milestones including pivotal trial initiation for IMPT-314."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-248760","json":"https://secwatch.observer/filing/0001193125-24-248760.json","markdown":"https://secwatch.observer/filing/0001193125-24-248760.md","text":"https://secwatch.observer/filing/0001193125-24-248760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/0001193125-24-248760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/d901554d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:35:18.718212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ff27901a9","claim":"Sumant Ramachandra was appointed as Class III director at Lyell Immunopharma, Inc..","evidence_excerpt":"Sumant Ramachandra, M.D., Ph.D., who was the Chief Executive Officer and a director of ImmPACT prior to the consummation of the Merger, was appointed as a Class III director to the Board of Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/0001193125-24-248760-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"},{"claim_id":"c78babdcd1ae904e58af79ea56cd77f666c2ce7b","claim":"Lyell Immunopharma, Inc. completed an acquisition involving ImmPACT Bio USA Inc. for $30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock (closed 2024-10-31).","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, on the Closing Date, the Company acquired all of the outstanding equity interests of ImmPACT in exchange for an upfront payment of $30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock. The acquisition was effected via a","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/0001193125-24-248760-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"ImmPACT Bio USA Inc."},{"label":"Consideration","value":"$30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock"},{"label":"Closing","value":"2024-10-31"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}